ReviewJournal of herbal medicine2020
Potential benefits of combination of
Review in Journal of herbal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 66 citations in OpenAlex.
- Trial
- Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025Review
- Antimicrobial Properties and Therapeutic Potential of Bioactive Compounds inMolecules (Basel, Switzerland) · 2024Review
- Soy protein isolate film activated by black seed oil nanoemulsion as a novel packaging for shelf-life extension of bulk bread.Food science & nutrition · 2024Article
- Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection.Frontiers in pharmacology · 2024Article
- Predicting phytochemical diversity of medicinal and aromatic plants (MAPs) across eco-climatic zones and elevation in Uttarakhand using Generalized Additive Model.Scientific reports · 2023Article
- COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.Genes & diseases · 2023Review
- Strategies for the Management of Spike Protein-Related Pathology.Microorganisms · 2023Review
- Mechanism of the antidiabetic action ofFrontiers in nutrition · 2023Review
- Natural Products as a Potential Source of Promising Therapeutics for COVID-19 and Viral Diseases.Evidence-based complementary and alternative medicine : eCAM · 2023Review
- Ethnopharmacological Potential of Phytochemicals and Phytogenic Products against Human RNA Viral Diseases as Preventive Therapeutics.BioMed research international · 2023Review
- In Silico Studies on Zinc Oxide Based Nanostructured Oil Carriers with Seed Extracts ofMolecules (Basel, Switzerland) · 2022Article
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2.Pathogens (Basel, Switzerland) · 2022Article
- Prevention, treatment and potential mechanism of herbal medicine for Corona viruses: A review.Bioengineered · 2022Review
- Natural products can be used in therapeutic management of COVID-19: Probable mechanistic insights.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge.Frontiers in pharmacology · 2022Review
- The potential role of thymoquinone in preventing the cardiovascular complications of COVID-19.Vascular pharmacology · 2021Review
- Possible therapeutic effects ofPharmaceutical biology · 2021Review
- Computational Identification of Dithymoquinone as a Potential Inhibitor of Myostatin and Regulator of Muscle Mass.Molecules (Basel, Switzerland) · 2021Article
- Thymoquinone against infectious diseases: Perspectives in recent pandemics and future therapeutics.Iranian journal of basic medical sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An effective vaccine to prevent the SARS-CoV-2 causing COVID-19 is yet to be approved. Further there is no drug that is specific to treat COVID-19. A number of antiviral drugs such as Ribavirin, Remdesivir, Lopinavir/ritonavir, Azithromycin and Doxycycline have been recommended or are being used to treat COVID-19 patients. In addition to these drugs, rationale and evidence have been presented to use chloroquine to treat COVID-19, arguably with certain precautions and criticism. In line with the proposed use of chloroquine, Nigella sativa (black seed) could be considered as a natural substitute that contains a number of bioactive components such as thymoquinone, dithymoquinone, thymohydroquinone, and nigellimine. Further benefits to use
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.